The 2020 State of Cannabinoids
- There is a considerable amount of misinformation about the Endocannabinoid System
- Currently there no standard guidelines for cannabinoids because they have removed it from under the nutritional supplement umbrella due to a new pharmaceutically made isolate CBD product approved for seizures.
- The World Health Organization (WHO) listing 17 diseases where CBD “may have therapeutic benefits” and the clearing of CBD from the World Anti-doping Agency list of prohibited substances.
- With over 30,000 studies and 30 million dollars in research already done and more happening all over the world Sucavu will be using that information to create better targeted products
Most of these opposing positions stem from misinformation about our own endocannabinoid system as well as confusing and conflicting information provided by governing bodies world wide, all tip toeing around the research.
In the US, we have the FDA who would normally regulate natural plant products. However, currently there no standard guidelines for cannabinoids because they have removed it from under the nutritional supplement umbrella due to a new pharmaceutically made isolate CBD product approved for seizures. This unfortunately diminished regulation of quality and labeling focusing it’s efforts based on general disdain of any health claims. This position by the FDA opposes the general populace who want the government to give cannabinoids back to “the people”. Unfortunately “ the people” do not understanding some of the inherent dangers of toxins pulled out because of the soil remediation benefits of the plant. In fact there were over 1500 reported poisonings to the National poison control center leading to a relative nightmare of no regulation and unscrupulous companies with dangerous products on the market just looking to make a quick buck. In 2019 over 1500 US poison control center cases were filed and already 144 cases in January 2020 .